Osimertinib

Osimertinib is an oral targeted medicine for selected adults with non-small cell lung cancer (NSCLC) whose tumors carry specific activating EGFR mutations; its exact role depends on stage and prior treatment.

Osimertinib is a small-molecule kinase inhibitor that binds irreversibly to certain mutant forms of EGFR, including common sensitizing mutations and the T790M resistance mutation. Blocking EGFR phosphorylation suppresses downstream growth and survival signaling. It was designed to inhibit mutant EGFR more selectively than earlier EGFR inhibitors, although normal-tissue EGFR effects still contribute to rash, diarrhea, nail changes, and other adverse effects. [O1, O2]

The drug and active metabolites reach the central nervous system, which is clinically relevant because EGFR-mutated NSCLC frequently spreads to the brain. CNS activity does not eliminate the need for brain imaging or local treatment when clinically indicated. [O1, O3, O4]

In the current U.S. label, osimertinib is used only in EGFR mutation-positive NSCLC, not as a general treatment for all lung cancers. FDA-authorized testing is required for the relevant mutation. [O1]

After complete tumor resection, as adjuvant therapy for adults with NSCLC containing EGFR exon 19 deletion or exon 21 L858R mutations. [O1, O5]

For unresectable stage III NSCLC with the same common EGFR mutations when disease has not progressed during or after definitive platinum-based chemoradiation. [O1, O3]

As first-line treatment for locally advanced or metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R. [O1, O2]

In combination with pemetrexed and platinum chemotherapy as first-line therapy for locally advanced or metastatic NSCLC with these common EGFR mutations. [O1, O4, O8]

For metastatic EGFR T790M-positive NSCLC that has progressed on or after earlier EGFR-TKI therapy. [O1]

Required predictive biomarkers: EGFR exon 19 deletion and EGFR exon 21 L858R substitution are the main common sensitizing alterations specified in the current label. EGFR T790M is required for the post-EGFR-TKI indication specifically labeled for T790M-positive metastatic disease. [O1]

Testing considerations: Tumor tissue or a validated plasma circulating-tumor-DNA assay may be used in appropriate settings. A negative plasma result can be false-negative because some tumors shed little DNA; tissue testing should be considered when feasible and clinically appropriate. Mutation wording matters — not every rare EGFR alteration has the same sensitivity, and an EGFR exon 20 insertion is biologically different from the common exon 19 deletion. [O1, O9]

At progression, repeat tissue or plasma profiling may identify resistance mechanisms and histologic transformation. Results should be interpreted in context because a liquid biopsy may miss alterations, and a tissue biopsy samples only one site. [O6]

Osimertinib is administered orally as a tablet. This document intentionally omits dose, schedule, dose modification, and tablet-dispersion instructions. Strong CYP3A inducers can substantially lower exposure and should generally be avoided; the oncology team should review prescription medicines, over-the-counter drugs, and herbal products. [O1]

Common clinical or laboratory adverse effects in the label include diarrhea, rash, dry skin, nail toxicity, mouth inflammation, fatigue, musculoskeletal pain, and reductions in blood-cell counts. When given with platinum-pemetrexed chemotherapy, chemotherapy-related marrow suppression, kidney-function changes, and other toxicities become more prominent. Frequency varies by disease setting and combination. [O1]

Interstitial lung disease (ILD)/pneumonitis, which may be severe or fatal. New or worsening cough, shortness of breath, or fever requires prompt assessment. [O1]

QTc interval prolongation and potentially serious rhythm disturbance; ECG and electrolyte monitoring is important for selected patients. [O1]

Cardiomyopathy or reduced left-ventricular ejection fraction, especially in people with cardiac risk factors. [O1]

Keratitis and other eye symptoms requiring ophthalmologic evaluation. [O1]

Rare severe skin reactions, including erythema multiforme major, Stevens-Johnson syndrome, toxic epidermal necrolysis, and cutaneous vasculitis. [O1]

Rare aplastic anemia and other clinically important cytopenias. [O1]

Embryo-fetal harm; pregnancy and contraception counseling are required. [O1]

Symptoms of pneumonitis/ILD throughout treatment; imaging and interruption may be needed if suspected. [O1]

Complete blood counts; liver and kidney function according to the treatment plan, especially with chemotherapy. [O1]

ECG and electrolytes when there is a history or risk of QT prolongation or use of other QT-prolonging medicines. [O1]

LVEF in patients with cardiac risk factors or symptoms of heart failure. [O1]

Eye evaluation for pain, light sensitivity, tearing, blurred vision, or other possible keratitis symptoms. [O1]

Strong CYP3A inducers can reduce osimertinib exposure and may compromise effectiveness. Osimertinib can also affect exposure to selected transporter substrates, and the complete medication list should be reviewed. Combining multiple QT-prolonging agents may increase cardiac risk. Interaction management is individualized and should not be attempted without the oncology and pharmacy teams. [O1]

Only patients with an appropriate EGFR alteration should receive osimertinib for the labeled indications; "EGFR-positive" is too imprecise without the exact variant. [O1]

A response is not guaranteed, and acquired resistance eventually develops in many advanced cancers. [O6]

The monotherapy and chemotherapy-combination approaches have different toxicity burdens and are not interchangeable choices for every patient. [O1, O4]

Safety management after recent thoracic chemoradiation requires particular attention because radiation pneumonitis and drug-related ILD can overlap. [O1, O3]

This profile does not cover unapproved rare-EGFR uses, off-label combinations, or exact treatment duration. [O1]

Acquired resistance is heterogeneous. Reported mechanisms include bypass signaling such as MET amplification; secondary EGFR alterations such as C797S; activation of HER2, RAS-MAPK, or PI3K pathways; and histologic transformation, including transformation to small-cell lung cancer. A 2023 analysis identified MET amplification and EGFR C797S among the most frequent candidate mechanisms after first-line osimertinib, but no single mechanism explained all cases. [O6]

Resistance testing can influence clinical-trial selection or subsequent therapy, but the presence of a resistance alteration does not automatically prove that a specific next treatment will work. [O6]

ADAURA established adjuvant osimertinib after resection for common EGFR-mutated NSCLC and later reported an overall-survival benefit. [O5]

LAURA demonstrated benefit after definitive chemoradiation in unresectable stage III EGFR-mutated NSCLC and supported the 2024 U.S. indication. [O3]

FLAURA2 evaluated first-line osimertinib plus platinum-pemetrexed versus osimertinib alone; a later overall-survival analysis was published in 2026. [O4, O8]

Current research focuses on molecularly matched strategies after resistance, serial ctDNA, prevention of CNS relapse, and balancing added efficacy against chemotherapy toxicity. [O6]

Regulatory indications and safety language are summarized primarily from U.S. FDA prescribing information. Approval status, testing requirements, formulations, and recommended use may differ in other countries or change after this document is published.